glutathione PEGylated liposomal doxorubicin (2X-111) / Allarity Therap - LARVOL DELTA

ISET CTC-DNA shows higher sensitivity then ctDNA in early stage lung cancer patients (IASLC-WCLC 2025) - "Paired-end (2x111 bases) sequencing was performed on a MiSeq device (Illumina, Inc.)...Conclusions : (Preliminary): These preliminary results, if confirmed by the coming data from the whole cohort, suggest that CTC-DNA obtained with an hypersensitive approach could improve early stage lung cancer detection and early lung cancer recurrence detection by increasing the sensitivity of ctDNA-based results. Note: Further updated data from the 50 patients included in the study will be presented at the Conference."

Circulating tumor DNA • Clinical • Lung Cancer • Oncology • Solid Tumor • CTCs

The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre-insertion and post-insertion methods for brain delivery in normal mice. (PubMed, IET Nanobiotechnol) - "Here, the 5% pre-inserted PEG2000-GSH PEGylated liposomal doxorubicin was conducted according to 2B3-101 being tested in clinical trials...In comparison to the pre-insertion procedure, the post-insertion method is easier, faster, and more cost-effective. Moreover, employing PEG3400 and the post-insertion approach in the PEG3400-GSGGCE liposomal formulations was found to be effective in crossing the BBB."

Journal • Preclinical • Brain Cancer • Cardiovascular • Oncology • Solid Tumor

Preparation, characterization, and biodistribution of glutathione PEGylated nanoliposomal doxorubicin for brain drug delivery with a post-insertion approach. (PubMed, Iran J Basic Med Sci) - "The post-insertion technique was found a successful approach with more pharmaceutical aspects for large-scale production. Moreover, further investigations are highly recommended to determine the efficacy of 5% post-inserted GSH targeted nanoliposomes versus 2B3-101 as a similar formulation with a different preparation method."

Journal • Brain Cancer • Oncology • Solid Tumor

Allarity Therapeutics Gains Allowance from U.S. Patent and Trademark Office for New DRP Biomarker Patents (Streetinsider.com) - "Allarity Therapeutics A/S...announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance to the Company...U.S. Patent Application No.: 15/858,703, 'METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS' – Directed to a DRP^® biomarker for Cisplatin, including the Company’s cancer drug LiPlaCis®; U.S. Patent Application No.: 15/978,655, 'METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS' – Directed to DRP^® biomarkers for anthracyclines, including doxorubicin, epirubicin, and the Company’s cancer drug 2X-111..."

Biomarker • Patent • Breast Cancer • Glioblastoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology

[VIRTUAL] Demonstration of Fully Autonomous, Endoscopic Robot-Assisted Closure of Ventral Hernia using Smart Tissue Autonomous Robot (STAR)TM in Preclinical Porcine Model (SAGES 2020) - "The prototype 3-D 10 mm endoscope consisted of a chip-on-tip stereo camera, with camera housing dimension of 22.7x23.2x111.8 mm... For the first time, we report a successful demonstration of in vivo laparoscopic, fully autonomous robot-assisted ventral hernia repair in a preclinical porcine model. In addition, the ability to generate a 3-D point cloud without cumbersome fluorophore markers and improvements in the form factor, computer vision algorithms, real time 3-D tracking, and suturing algorithm are reported."

Preclinical

Pazopanib hydrochloride followed by chemotherapy and surgery in treating patients with soft tissue sarcoma (clinicaltrials.gov) - P=NA, N=25; Not yet recruiting -> Recruiting

Enrollment open • Oncology

Press release Oncology Venture acquires full ownership of its PARP inhibitor (2X-121) program (GlobeNewswire) - "Oncology Venture...announced...that it has secured the remaining ownership in its priority PARP inhibitor (2X-121) program along with its 2X-111 program, by acquiring all outstanding shares in Oncology Venture US Inc. (formerly 2X Oncology, Inc.) from its external shareholders and warrantholders. As a result of the transaction, the Company now has 100 % ownership of 2X-121, which is being clinically developed as an anti-cancer therapeutic..."

M&A • Oncology

Press release Oncology Venture signs agreement to out-license two pipeline assets as part of prioritized portfolio strategy (GlobeNewswire) - "Oncology Venture A/S....announced that it has signed a definitive agreement out-licensing two clinical pipeline assets, LiPlaCis® and 2X-111, to Smerud Medical Research International for further clinical and commercial development. Under the terms of the agreement, OV will receive regulatory milestone fees of nearly US $30M plus royalties on sales for each drug payable to OV if all the milestones are met. OV also terminated its prior license agreement with Cadila Pharmaceuticals for the development of LiPlaCis® in India....Under their new agreement, Smerud will advance the specific development of LiPlaCis® in late stage metastatic breast cancer and 2X-111 in glioblastoma multiforme, in connection with each program’s DRP® companion diagnostic."

Licensing / partnership • Breast Cancer • Glioblastoma • Oncology

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. (clinicaltrials.gov) - P1/2; N=84; Completed; Sponsor: BBB-Therapeutics B.V.; Active, not recruiting -> Completed ; Trial primary completion date: Sep 2014 ->Dec 2014

Trial completion • Trial primary completion date • Biosimilar • Breast Cancer • Melanoma • Oncology • Triple Negative Breast Cancer

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers (Gynecol Oncol) - P2, N=54; Study ID: DOXILOVC2007; Intent-to-treat (all enrolled pts) ORR was 72.2%; Median duration of response was 11.9 months & median TTP was 13.9 months; PFS was virtually the same as TTP; Three pts discontinued therapy due to disease progression & another three pts stopped due to SAEs (Grade 4 thrombocytopenia, Grade 3 small/large intestinal obstruction/small intestinal perforation & Grade 3 abdominal abscess)

P2 data • Oncology • Ovarian Cancer